Skip to main content
Omar Mian, MD, Radiation Oncology, Cleveland, OH

OmarYusufMianMDPhD

Radiation Oncology Cleveland, OH

Urologic Cancer

Physician

Dr. Mian is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Mian's full profile

Already have an account?

  • Office

    9500 Euclid Ave
    Cleveland, OH 44195
    Phone+1 216-444-2200
    Fax+1 216-444-9423

Summary

  • Dr. Omar Mian is a radiation oncologist in Cleveland, OH and is affiliated with Cleveland Clinic. He received his medical degree from Virginia Commonwealth University School of Medicine and completed residency at Johns Hopkins Hospital. He specializes in urologic cancer.

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Radiation Oncology, 2012 - 2016
  • Virginia Commonwealth University Health System
    Virginia Commonwealth University Health SystemResidency, Internal Medicine, 2011 - 2012
  • Virginia Commonwealth University School of Medicine
    Virginia Commonwealth University School of MedicineClass of 2011

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2016 - 2026
  • WA State Medical License
    WA State Medical License 2024 - 2025
  • American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

  • ACS Research Scholar Award American Cancer Society, 2020
  • NCCN Young Investigator Award National Comprehensive Cancer Network, 2020
  • SBUR Young Investigator Award Society of Basic Urologic Research, 2020
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Use of 5-alpha-reductase inhibitors as alternatives to luteinizinghormone releasing hormone (LHRH) analogs or anti-androgens for prostate downsizing before brachytherapy  
    Bae HJ, Mian Omar Y, Vaidya D, DeWeese TL, Song DY, Pract Radiat Oncol, 1/10/2017
  • Current controversies in prostate brachytherapy for prostate cancer  
    Ibrahim Abu-Gheida, Christopher Fleming, Paul Ramia, Omar Mian, Rahul Tendulkar and Jay Ciezki, MD, Applied Radiation Oncology, 1/1/2017
  • The evolving role of molecular profiling in prostate cancer: basal and luminal subtyping transcends tissue of origin  
    Mian OY, Tendulkar RD, Abazeed ME., Transl Cancer Res, 1/1/2017
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • Genetic and Epigenetic Profiling of Small Cell Bladder Cancer (SCBC).
    Petros Grivas, Vadim S. Koshkin, Jordan Reynolds, Paul Elson, Cristina Magi-Galluzzi, Jesse McKenney, Karen Streator Smith, Bonnie Shadrach, Kumiko Isse, Laura R. Saun..., ASTRO Annual Meeting, 1/1/2017
  • Molecular Profiling of Small Cell Bladder Cancer (SCBC) Reveals Gene Expression Determinants of an Aggressive Phenotype
    Vadim S. Koshkin, Jordan Reynolds, Paul Elson, Cristina Magi-Galluzzi, Jesse McKenney, Karen Streator Smith, Bonnie Shadrach, Kumiko Isse, Laura R. Saunders, Ming Hu, ..., ASCO Annual Meeting, 1/1/2017
  • DNA Methylation and H3K27M Mutant Allele Frequency as a biomarker of therapeutic response in DIPG
    Adam DeLong, Peter Anderson, Stephen Dombrowski, Erin Murphy, and Omar Mian, Lepow Day Research Presentation, CWRU SOM, 1/1/2017
  • Join now to see all

Lectures

  • Circulating tumor DNA (ctDNA) as a precision tool in radiotherapy. 
    Washington, DC - 1/4/2017
  • Controversies in the contemporary management of prostate cancer: Emerging role of biomarkers 
    Sheraton Hotel, Cordoba, Argentina - 1/2/2017
  • Dosimetric Predictors of Sexual Function Decline Following LDR Brachytherapy for Prostate Cancer (PCa) 
    San Antonio, TX - 1/1/2015
  • Join now to see all

Other

  • Integrated Molecular Profiling of GU Tumors: Applications for Personalized Therapy 
    Nature Webinar
    Nature.com
    1/28/2017
  • Thesis, The Role of the Methyl DNA Binding Domain Protein 2 (MBD2) in Breast Cancer 

Authored Content

  • Transcriptomic and Protein Analysis of Small Cell Bladder Cancer Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target - Beyond the AbstractDecember 2018
  • Persepctive - Stereotactic ablative radiotherapy for renal cell carcinoma safe in patients with solitary kidneyOctober 2018

Press Mentions

  • Real-World Data Suggest Benefit From SBRT Plus Pembro in Advanced Bladder Cancer
    Real-World Data Suggest Benefit From SBRT Plus Pembro in Advanced Bladder CancerOctober 1st, 2024
  • Genetic and Pathologic Characteristics of Small Cell Bladder Cancer
    Genetic and Pathologic Characteristics of Small Cell Bladder CancerNovember 13th, 2017
  • Trimodality Therapy for Invasive Bladder Cancer
    Trimodality Therapy for Invasive Bladder CancerMarch 14th, 2017
  • Join now to see all

Professional Memberships